ImmunityBio, Inc.
US ˙ NasdaqGS ˙ US45256X1037

SecurityIBRX / ImmunityBio, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership168,356 shares
Latest Disclosed Value $ 1,291,290
Citigroup Inc ownership in IBRX / ImmunityBio, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 168,356 shares of ImmunityBio, Inc. (US:IBRX) valued at $1,291,291 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 110,511 shares of ImmunityBio, Inc.. This represents a change in shares of 52.34% during the quarter. The current value of the position is $1,208,796 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (IBRX) in the form of stock options. The firm currently holds call options representing 50,000 of underlying shares valued at $383,500 USD and put options representing 50,000 of underlying shares valued at $383,500 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IBRX / ImmunityBio, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F IMMUNITYBIO COM 45256X103 168,356 57,845 52.34 1,291 492.20 0.0006
2026-02-13 2025-12-31 13F IMMUNITYBIO COM 45256X103 110,511 -2,271,488 -95.36 219 -96.28 0.0001
2025-11-10 2025-09-30 13F IMMUNITYBIO COM 45256X103 2,381,999 -104,879 -4.22 5,860 -10.75 0.0026
2025-08-11 2025-06-30 13F IMMUNITYBIO COM 45256X103 2,486,878 -227,784 -8.39 6,565 -19.65 0.0032
2025-05-12 2025-03-31 13F IMMUNITYBIO COM 45256X103 2,714,662 2,330,086 605.88 8,171 730.39 0.0042
2025-02-12 2024-12-31 13F IMMUNITYBIO COM 45256X103 384,576 274,706 250.03 985 141.18 0.0006
2024-11-12 2024-09-30 13F IMMUNITYBIO COM 45256X103 109,870 884 0.81 409 -40.70 0.0002
2024-08-12 2024-06-30 13F IMMUNITYBIO COM 45256X103 108,986 -1,019,460 -90.34 689 -88.64 0.0004
2024-05-10 2024-03-31 13F IMMUNITYBIO COM 45256X103 1,128,446 816,424 261.66 6,060 286.91 0.0040
2024-02-09 2023-12-31 13F IMMUNITYBIO COM 45256X103 312,022 305,990 5,072.78 1,566 15,560.00 0.0011
2023-12-06 2023-09-30 13F/A-1 IMMUNITYBIO COM 45256X103 6,032 -37,482 -86.14 10 -91.67 0.0000
2023-11-09 2023-09-30 13F IMMUNITYBIO COM 45256X103 6,032 -37,482 10 0.0000
2023-08-10 2023-06-30 13F IMMUNITYBIO COM 45256X103 43,514 35,783 462.85 121 757.14 0.0001
2023-05-11 2023-03-31 13F IMMUNITYBIO COM 45256X103 7,731 -204,874 -96.36 14 -98.70 0.0000
2023-02-09 2022-12-31 13F IMMUNITYBIO COM 45256X103 212,605 -161,039 -43.10 1,078 -42.00 0.0009
2022-11-10 2022-09-30 13F IMMUNITYBIO COM 45256X103 373,644 358,916 2,436.96 1,857 3,276.36 0.0013
2022-08-10 2022-06-30 13F IMMUNITYBIO COM 45256X103 14,728 -78,444 -84.19 55 -89.48 0.0000
2022-05-12 2022-03-31 13F IMMUNITYBIO COM 45256X103 93,172 -290,323 -75.70 523 -77.57 0.0003
2022-02-10 2021-12-31 13F IMMUNITYBIO COM 45256X103 383,495 199,019 107.88 2,332 29.77 0.0012
2021-11-10 2021-09-30 13F IMMUNITYBIO COM 45256X103 184,476 -115,637 -38.53 1,797 -58.07 0.0011
2021-08-10 2021-06-30 13F IMMUNITYBIO COM 45256X103 300,113 129,865 76.28 4,286 6.04 0.0026
2021-05-13 2021-03-31 13F IMMUNITYBIO COM 45256X103 170,248 141,217 486.44 4,042 944.44 0.0026
2021-02-11 2020-12-31 13F NANTKWEST COM 63016Q102 29,031 25,853 813.50 387 1,659.09 0.0002
2020-11-12 2020-09-30 13F NANTKWEST COM 63016Q102 3,178 -750 -19.09 22 -54.17 0.0000
2020-08-12 2020-06-30 13F NANTKWEST COM 63016Q102 3,928 989 33.65 48 500.00 0.0000
2020-05-12 2020-03-31 13F NANTKWEST COM 63016Q102 2,939 -241 -7.58 8 -33.33 0.0000
2020-02-12 2019-12-31 13F NANTKWEST COM 63016Q102 3,180 0 0.00 12 200.00 0.0000
2019-11-08 2019-09-30 13F NANTKWEST COM 63016Q102 3,180 -1,068 -25.14 4 0.00 0.0000
2019-08-12 2019-06-30 13F NANTKWEST COM 63016Q102 4,248 -2,714 -38.98 4 -63.64 0.0000
2019-05-13 2019-03-31 13F NANTKWEST COM 63016Q102 6,962 -7,051 -50.32 11 -35.29 0.0000
2019-02-12 2018-12-31 13F NANTKWEST COM 63016Q102 14,013 8,216 141.73 17 -22.73 0.0000
2018-11-13 2018-09-30 13F NANTKWEST COM 63016Q102 5,797 2,294 65.49 22 100.00 0.0000
2018-08-10 2018-06-30 13F NANTKWEST COM 63016Q102 3,503 3,244 1,252.51 11 1,000.00 0.0000
2018-05-11 2018-03-31 13F NANTKWEST COM 63016Q102 259 -6,812 -96.34 1 -96.87 0.0000
2018-02-12 2017-12-31 13F NANTKWEST COM 63016Q102 7,071 3,818 117.37 32 77.78 0.0000
2017-11-13 2017-09-30 13F NANTKWEST COM 63016Q102 3,253 2,061 172.90 18 100.00 0.0000
2017-08-11 2017-06-30 13F NANTKWEST COM 63016Q102 1,192 -4,986 -80.71 9 -57.14 0.0000
2017-05-12 2017-03-31 13F NANTKWEST COM 63016Q102 6,178 -16,008 -72.15 21 -83.46 0.0000
2017-02-10 2016-12-31 13F NANTKWEST COM 63016Q102 22,186 7,195 48.00 127 8.55 0.0001
2016-11-10 2016-09-30 13F NANTKWEST COM 63016Q102 14,991 390 2.67 117 28.57 0.0001
2016-08-12 2016-06-30 13F NANTKWEST COM 63016Q102 14,601 -2,480 -14.52 91 -35.00 0.0001
2016-05-13 2016-03-31 13F NANTKWEST COM 63016Q102 17,081 428 2.57 140 -51.39 0.0002
2016-02-12 2015-12-31 13F NANTKWEST COM 63016Q102 16,653 10,352 164.29 288 300.00 0.0003
2015-11-13 2015-09-30 13F NANTKWEST COM 63016Q102 6,301 6,301 72 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F IMMUNITYBIO COM Call 50,000 384 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F IMMUNITYBIO COM Put 50,000 384 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.